ライフサイエンスコーパス: weight decrease

1 cartilage damage, bone resorption, and body weight decrease.

2 xol((R)) resulted in toxicity issues as body weight decreased.

3 Weight decreased 0.2 lb in the intervention and increase

4 However, birth weights decreased (15% after one dose, 19% after two dos

5 s), diarrhoea (17 [9%]), asthenia (16 [8%]), weight decrease (16 [8%]), and PPE (14 [7%]); common gra

6 ients), hypertension (92 [49%] vs 28 [29%]), weight decrease (69 [37%] vs 23 [24%]), decreased appeti

7 gluteal and iliac lymph nodes (maximum nodal weight decreases, 86% and 88% from control values, respe

8 ntile regression models indicated that birth weight decreased across the entire distribution, but red

9 n showed significant viscosity and molecular weight decrease after 1 week of oxidation at room temper

10 ts In the dietary group, fat intake and body weight decreased (all P < .001).

11 Hence, as body weight decreased and agouti-related protein is induced,

12 lative reliabilities of the two cues: visual weights decrease and vestibular weights increase when vi

13 Body weight decreased as expected after surgery.

14 f the traditional catalyst system, molecular weights decrease as the level of comonomer increases and

15 Initial weight decreased at least 5% in 21.5%, 26.0%, and 34.9%

16 71.9 mg/g during baking, but their molecular weight decreased at the beginning of the process and inc

17 MI trajectories were identified: "low-normal weight, decreasing" (baseline BMI = 18.7; 23.8% of sampl

18 ne BMI = 18.7; 23.8% of sample); "mid-normal weight, decreasing" (baseline BMI = 21.9; 44.6% of sampl

19 e BMI = 21.9; 44.6% of sample); "high-normal weight, decreasing" (baseline BMI = 24.8; 26.5% of sampl

20 ticular, relative to those with a mid-normal weight, decreasing BMI trajectory, those with an overwei

21 ncreased plasma estradiol, increased uterine weight, decreased body weight, decreased visceral adipos

22 Body weight decreased by 0.92 to 1.61 kg with dapagliflozin a

23 Weight decreased by 1.8 kg with exenatide and increased

24 Body weight decreased by 10% in the diet group and by 9% in t

25 In the WL group, body weight decreased by 10.2 +/- 5.5% (P < 0.001), body fat

26 acteristics, and pregnancy conditions, birth weight decreased by 2.20 g per year (P < 0.0001).

27 emained active after water deprivation, body weight decreased by 20-22%, serum osmolality remained no

28 Body weight decreased by 35 +/- 2%, serum osmolality increase

29 intake decreased by 441 +/- 63 kcal/d, body weight decreased by 4.9 +/- 0.5 kg, and fat mass decreas

30 Body weight decreased by 7% (7 kg [SD, 1]) in the diet group,

31 Body weight decreased by 8.4% (8.2 kg) in the treatment group

32 Body weight decreased by 9% in all exercise groups but did no

33 triction increased >6-fold, and infant birth weight decreased by approximately 200 g.

34 lution of hepatic yellow coloration; hepatic weight decreased by approximately 36% compared to PBS-tr

35 ysplasia, long bone length shortage and body weight decrease compared with wild-type littermates.

36 showed comparable anatomic (mean hemispheric weight decrease: control 42%, HPC 25% (P=0.01), HBO-PC 2

37 The brain weight decreases during aging in conjunction with severe

38 e, increased insulin sensitivity, lower body weight, decreased fat mass, and a complete reversal of h

39 The resulting effect was a lower body weight, decreased fat mass, and reduced leptin levels.

40 l-identified disabilities increased as birth weight decreased for all birth weight strata of <or=3,49

41 The 18-month intervention resulted in weight decreasing from 93.1 kg (95% CI, 91.0 to 95.2 kg)

42 e knockout seeds had approximately 3% of dry weight decrease in oil content compared with that of the

43 There was a significant fetal weight decrease in the IUGR FPUs (-21.9%; P < .001).

44 number of metals and ligands, the molecular weight decrease in the metal-rich area is caused by an i

45 The feces weight decreased in buserelin-treated rats (p < 0.01), w

46 or males (all P>0.44), although body fat and weight decreased in exposed females at particular ages (

47 Weight decreased in the demand group by 4.8 +/- 2.0 kg,

48 lic acid ratios as demonstrated by molecular weight decrease, lactic acid release, and thermal proper

49 Body weights decreased less than 10% in all groups.

50 initial 4 weeks of therapy, a mean absolute weight decrease of 0.4 kg was observed for all patients.

51 .66 to 1.37; I(2)=82%), and led to a greater weight decrease only when compared with a usual diet (ei

52 ragments (S-O-PG) (240 micrograms/kg of body weight) decreased overnight food consumption in male Lew

53 Body weight decreased (P < 0.001) by 5.6 +/- 1.0 kg (5.8 +/-

54 ed to increase their energy intakes as their weights decreased (p for trend < 0.002).

55 increased from 2- to 8-fold, adult prostate weight decreased relative to males exposed to the 50% in

56 Body weight decreased significantly (1.53 kg; P < 0.001) only

57 or African-American mothers only, mean birth weight decreased significantly as the neighborhood level

58 Patients' relative weight decreased significantly but only slightly, with t

59 inine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl

60 Body weight decreased significantly over a 6-mo intensive int

61 irus, as characterized by rapid loss of body weight, decreased survival time, and decreased mean leth

62 ary to determine whether a reduction in body weight decreases the risk of stone formation, particular

63 6.7+/-60.0 hrs, during which time their body weight decreased to 30%+/-12% above admission weight (p<

64 d; when digested with 100 U/gel, the gel wet weight decreased (to 57% of original wet weight versus 8

65 ol, increased uterine weight, decreased body weight, decreased visceral adiposity, and enhanced gluco

66 Body weight decreased with liraglutide compared with placebo